Enzyme replacement or substrate reduction? A review of gaucher disease treatment options

Hospital Pharmacy

Volumn 51, Issue 7, 2016, Pages 553-563

  Van Rossum, Alison ^a   Holsopple, Megan ^b  

^a UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Enzyme replacement; Gaucher disease; Lysosomal storage disease; Substrate reduction

Indexed keywords

ELIGLUSTAT; IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

DRUG EFFICACY; ENZYME REPLACEMENT; ENZYME THERAPY; GAUCHER DISEASE; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUBSTRATE REDUCTION THERAPY;

EID: 84986628114     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj5107-553     Document Type: Review

References (28)

1. Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine. 2008;75(2):116-124.
2. Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182-1193.
3. Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53(4):274-276.
4. Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543-553.
5. Gaucher disease. Bethesda, MD: Genetics Home Reference. 2014. http://ghr.nlm.nih.gov/condition/gaucher-disease. Accessed June 22, 2015.
6. Gaucher's disease. Bethesda, MD: National Library of Medicine. 2014. http://www.nlm.nih.gov/medlineplus/gauchersdisease.html. Accessed June 2015.
7. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: A history and perspective. Drug Des Devel Ther. 2012;6:81-106.
8. Gaucher disease. Danbury, CT: National Organization for Rare Diseases. 2014. https://www.rarediseases.org/raredisease-information/rare-diseases/byID/12/printFullReport. Accessed April 23, 2015.
9. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 suppl 5):4-14.
10. Gaucher disease: A strategic collaborative approach from EMA and FDA. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2014/05/WC500166587.pdf. Accessed December 24, 2015.
11. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355(9214):1481-1485.
12. Cox TM, Amato D, Hollak CE, et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: A prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102.
13. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767-5773.
14. US Food and Drug Administration. Prescription and over-the-counter drug product list. 2012. http://www.fda. gov/downloads/drugs/informationondrugs/ucm300963.pdf. Accessed June 22, 2015.
15. US Food and Drug Administration. Drugs @ FDA: Imiglucerase (Cerezyme). 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Drug-Details. Accessed June 22, 2015.
16. US Food and Drug Administration. Drugs @ FDA: Velaglucerase alfa (Vpriv). 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Drug-Details. Accessed June 22, 2015.
17. Ben Turkia H, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88(3):179-184.
18. Zimran A, Pastores GM, Tylki-Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013;88(3):172-178.
19. Pastores GM, Petakov M, Giraldo P, et al. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53(4):253-260.
20. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893-899.
21. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 18 2010;116(20):4095-4098.
22. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial. Lancet. 13 2015;385(9985):2355-2362.
23. US Food and Drug Administration. Drugs @ FDA: Taliglucerase alfa (Elelyso). 2015.
24. Imiglucerase (Cerezyme) for injection [product information]. Cambridge, MA: Genzyme Corp.; 2005.
25. Taliglucerase (Elelyso) for injection [product information]. New York: Pfizer Laboratories; 2014.
26. Velaglucerase (Vpriv) for injection [product information]. Lexington, MA: Shire Human Genetic Therapies; 2013.
27. Miglustat (Zavesca) oral capsules [product information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc.; 2014.
28. Eliglustat (Cerdelga) oral capsules [product information]. Cambridge, MA: Genzyme Corp.; 2014.